Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRAME family member 26 (PRAMEF26) is a human protein-coding gene belonging to the PRAME family, characterized by leucine-rich repeats associated with protein-protein interactions[1][6]. PRAMEF26 is predicted to act as a substrate adaptor within Cullin2-RING E3 ubiquitin ligase complexes, potentially facilitating proteasome-mediated degradation of target proteins in the cytoplasm[2]. Its molecular function and involvement in disease remain largely uncharacterized, and there is no published evidence indicating PRAMEF26's use as a receptor, drug target, or biomarker[2][3][6]. Key distinctions and clarifications: - PRAMEF26 is not the same as PRAME (preferably used for the well-characterized cancer antigen). - PRAMEF26 is a substrate-adaptor protein, not a receptor, enzyme, transporter, channel, or transcription factor[2][6]. - No disease or drug involvement specific to PRAMEF26 is documented. - Nomenclature is correct per standard genomic sources (HGNC; GeneCards; UniProt)[2][6]. If more detailed, structured, or mechanistic biological information is required, future research may be necessary, as current knowledge is limited to predicted roles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PRAME family member 26 (PRAMEF26).